Exelixis, Inc. reported its third quarter 2026 financial results, showing an increase in total revenues to $658.7 million compared to $597.8 million for the same period in 2025. GAAP net income rose to $218.1 million, or $0.85 per diluted share, driven by higher net product sales from the cabozantinib franchise.
Total revenues for the quarter ended September 30, 2026, were $658.7 million, up from $597.8 million in the third quarter of 2025.
GAAP net income for the third quarter of 2026 was $218.1 million, or $0.85 per diluted share.
Cabozantinib franchise U.S. net product revenues reached $604.9 million for the quarter.
Exelixis updated its full-year 2026 financial guidance, including total revenues projected between $2.500 billion and $2.550 billion.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Exelixis's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2026
$2.32B
+7.0%
$2.78
+58.0%
33.7%
FY2025
$2.17B
+18.5%
$1.76
+170.8%
24.0%
FY2023
$1.83B
+13.6%
$0.65
+16.1%
11.4%
FY2022
$1.61B
+12.3%
$0.56
-22.2%
11.3%
FY2021
$1.43B
+45.3%
$0.72
+105.7%
16.1%
Frequently asked questions
When is Exelixis's next earnings date?
Exelixis has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Exelixis earn last quarter?
For the quarter ended Oct 2026, Exelixis reported diluted EPS of $0.85 (+23.2% year over year) on revenue of $658.70M (+10.2%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.